2025 Q2 -tulosraportti
202 päivää sitten
‧37 min
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 000 | - | - | ||
| 1 000 | - | - | ||
| 8 991 | - | - | ||
| 1 059 | - | - | ||
| 8 850 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·19 min sittenAnalyst Group considers that Circio's selection for an oral presentation at ASGCT 2026 is a qualitatively positive milestone which, seen in conjunction with the company's recently reported preclinical data, strengthens the increasing credibility of the circVec platform. Analyst Group assesses that the combination of a strengthened data foundation, an upcoming high-profile scientific presentation, and a strong balance sheet positions Circio favorably for deepened partner dialogues and broader industry recognition in the coming months. (Retrieved by Analystgroup.se)
37 min sitten37 min sittenAnalyst Group assesses that presenting circVec’s cross-tissue validation, including approx. 10x outperformance retained even at a 90% reduced dose level, could meaningfully advance Circio’s visibility among potential licensing partners at a time when circular RNA is attracting significant Big Pharma attention. This is underscored by Bristol Myers Squibb’s acquisition of Orbital Therapeutics for USD 1.5bn in Q4-25 and Eli Lilly’s acquisition of Orna Therapeutics for up to USD 2.4bn in Q1-26, reflecting the strategic premium large pharmaceutical companies are willing to assign to differentiated RNA expression technologies.
50 min sitten50 min sittenComment on Circio Holding’s Selection for Oral Presentation at ASGCT 2026 https://analystgroup.se/kommentarer/comment-on-circio-holdings-selection-for-oral-presentation-at-asgct-2026/·23 min sittenThis cannot in ANY way be interpreted as negative. You are indeed destructive and skeptical if you manage to find anything negative with this news.- 1 t sitten · Muokattu1 t sitten · MuokattuTomorrow heavely up 👌 It was very good news today ��
1 t sitten1 t sittenCircio selected for oral presentation at prestigious ASGCT annual meeting An abstract submitted by Circio has been selected for an oral presentation at the ASGCT annual meeting in Boston 11-15 May 2026 ASGCT is the most important and prestigious global gene and cell therapy conference The abstract publication date is 13 April 2026 Oslo, Norway, 18 March 2026 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, today announces that it has been selected for an oral presentation at the American Society of Gene and Cell Therapy annual meeting in Boston 11-15 May 2026. The ASGCT annual meeting is the largest and most prestigious gene and cell therapy conference globally, and widely attended by pharmaceutical and biotech professionals, academics and life science media. Only a small number of submitted abstracts are accepted for oral presentation. “ASGCT is the most important event of the year in our field, and we are very honored that the scientific committee has selected one of Circio´s gene therapy abstracts for an oral presentation,” said Dr. Thomas B Hansen, CTO of Circio. “This is an ideal opportunity to demonstrate to a broad industry audience how our circVec technology platform significantly enhances traditional gene and cell therapies. It is also an important arena to meet with both existing and prospective partners to support our R&D goals and create future business opportunities.” Circio has submitted two abstracts for ASGCT 2026, of which one has been selected for oral presentation and one for poster presentation. Further information about the Circio presentations and the full abstract texts will be released on the general abstract publication date, 13 April 2026.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q2 -tulosraportti
202 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·19 min sittenAnalyst Group considers that Circio's selection for an oral presentation at ASGCT 2026 is a qualitatively positive milestone which, seen in conjunction with the company's recently reported preclinical data, strengthens the increasing credibility of the circVec platform. Analyst Group assesses that the combination of a strengthened data foundation, an upcoming high-profile scientific presentation, and a strong balance sheet positions Circio favorably for deepened partner dialogues and broader industry recognition in the coming months. (Retrieved by Analystgroup.se)
- 37 min sitten37 min sittenAnalyst Group assesses that presenting circVec’s cross-tissue validation, including approx. 10x outperformance retained even at a 90% reduced dose level, could meaningfully advance Circio’s visibility among potential licensing partners at a time when circular RNA is attracting significant Big Pharma attention. This is underscored by Bristol Myers Squibb’s acquisition of Orbital Therapeutics for USD 1.5bn in Q4-25 and Eli Lilly’s acquisition of Orna Therapeutics for up to USD 2.4bn in Q1-26, reflecting the strategic premium large pharmaceutical companies are willing to assign to differentiated RNA expression technologies.
- 50 min sitten50 min sittenComment on Circio Holding’s Selection for Oral Presentation at ASGCT 2026 https://analystgroup.se/kommentarer/comment-on-circio-holdings-selection-for-oral-presentation-at-asgct-2026/·23 min sittenThis cannot in ANY way be interpreted as negative. You are indeed destructive and skeptical if you manage to find anything negative with this news.
- 1 t sitten · Muokattu1 t sitten · MuokattuTomorrow heavely up 👌 It was very good news today ��
- 1 t sitten1 t sittenCircio selected for oral presentation at prestigious ASGCT annual meeting An abstract submitted by Circio has been selected for an oral presentation at the ASGCT annual meeting in Boston 11-15 May 2026 ASGCT is the most important and prestigious global gene and cell therapy conference The abstract publication date is 13 April 2026 Oslo, Norway, 18 March 2026 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, today announces that it has been selected for an oral presentation at the American Society of Gene and Cell Therapy annual meeting in Boston 11-15 May 2026. The ASGCT annual meeting is the largest and most prestigious gene and cell therapy conference globally, and widely attended by pharmaceutical and biotech professionals, academics and life science media. Only a small number of submitted abstracts are accepted for oral presentation. “ASGCT is the most important event of the year in our field, and we are very honored that the scientific committee has selected one of Circio´s gene therapy abstracts for an oral presentation,” said Dr. Thomas B Hansen, CTO of Circio. “This is an ideal opportunity to demonstrate to a broad industry audience how our circVec technology platform significantly enhances traditional gene and cell therapies. It is also an important arena to meet with both existing and prospective partners to support our R&D goals and create future business opportunities.” Circio has submitted two abstracts for ASGCT 2026, of which one has been selected for oral presentation and one for poster presentation. Further information about the Circio presentations and the full abstract texts will be released on the general abstract publication date, 13 April 2026.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 000 | - | - | ||
| 1 000 | - | - | ||
| 8 991 | - | - | ||
| 1 059 | - | - | ||
| 8 850 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
2025 Q2 -tulosraportti
202 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·19 min sittenAnalyst Group considers that Circio's selection for an oral presentation at ASGCT 2026 is a qualitatively positive milestone which, seen in conjunction with the company's recently reported preclinical data, strengthens the increasing credibility of the circVec platform. Analyst Group assesses that the combination of a strengthened data foundation, an upcoming high-profile scientific presentation, and a strong balance sheet positions Circio favorably for deepened partner dialogues and broader industry recognition in the coming months. (Retrieved by Analystgroup.se)
- 37 min sitten37 min sittenAnalyst Group assesses that presenting circVec’s cross-tissue validation, including approx. 10x outperformance retained even at a 90% reduced dose level, could meaningfully advance Circio’s visibility among potential licensing partners at a time when circular RNA is attracting significant Big Pharma attention. This is underscored by Bristol Myers Squibb’s acquisition of Orbital Therapeutics for USD 1.5bn in Q4-25 and Eli Lilly’s acquisition of Orna Therapeutics for up to USD 2.4bn in Q1-26, reflecting the strategic premium large pharmaceutical companies are willing to assign to differentiated RNA expression technologies.
- 50 min sitten50 min sittenComment on Circio Holding’s Selection for Oral Presentation at ASGCT 2026 https://analystgroup.se/kommentarer/comment-on-circio-holdings-selection-for-oral-presentation-at-asgct-2026/·23 min sittenThis cannot in ANY way be interpreted as negative. You are indeed destructive and skeptical if you manage to find anything negative with this news.
- 1 t sitten · Muokattu1 t sitten · MuokattuTomorrow heavely up 👌 It was very good news today ��
- 1 t sitten1 t sittenCircio selected for oral presentation at prestigious ASGCT annual meeting An abstract submitted by Circio has been selected for an oral presentation at the ASGCT annual meeting in Boston 11-15 May 2026 ASGCT is the most important and prestigious global gene and cell therapy conference The abstract publication date is 13 April 2026 Oslo, Norway, 18 March 2026 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, today announces that it has been selected for an oral presentation at the American Society of Gene and Cell Therapy annual meeting in Boston 11-15 May 2026. The ASGCT annual meeting is the largest and most prestigious gene and cell therapy conference globally, and widely attended by pharmaceutical and biotech professionals, academics and life science media. Only a small number of submitted abstracts are accepted for oral presentation. “ASGCT is the most important event of the year in our field, and we are very honored that the scientific committee has selected one of Circio´s gene therapy abstracts for an oral presentation,” said Dr. Thomas B Hansen, CTO of Circio. “This is an ideal opportunity to demonstrate to a broad industry audience how our circVec technology platform significantly enhances traditional gene and cell therapies. It is also an important arena to meet with both existing and prospective partners to support our R&D goals and create future business opportunities.” Circio has submitted two abstracts for ASGCT 2026, of which one has been selected for oral presentation and one for poster presentation. Further information about the Circio presentations and the full abstract texts will be released on the general abstract publication date, 13 April 2026.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 000 | - | - | ||
| 1 000 | - | - | ||
| 8 991 | - | - | ||
| 1 059 | - | - | ||
| 8 850 | - | - |
Välittäjätilasto
Dataa ei löytynyt